Scientists Develop Chewing Gum That Fights 95% of Blood-Borne Viruses and Herpes

May 18, 2025
Health Innovation Oral Health Antiviral Technology
Micupost Digital News

May 2025 — Health & Science Desk — In a groundbreaking innovation, a team of international scientists has developed a chewing gum capable of neutralizing up to 95% of viruses present in the mouth — including herpes and several blood-borne pathogens. This discovery could revolutionize how we approach viral transmission and public health.


🧪 The Science Behind the Gum

The new antiviral chewing gum uses plant-derived proteins that bind to viral particles in the saliva, trapping and deactivating them before they can enter the bloodstream or be passed to others through droplets.

Key features:

  • Targets viruses like HSV-1 (oral herpes), HSV-2 (genital herpes), HIV, and hepatitis B & C
  • Reduces viral load in saliva by up to 95%
  • Can be used prophylactically or as a supplementary defense

“It’s like a molecular net that captures viruses before they can do harm,” said Dr. Elena Cruz, lead biochemist on the project.


🧬 How It Works

The gum contains ACE2 proteins and other antiviral enzymes that mimic human cell receptors. When viruses come into contact with these proteins, they bind to them and become inert, preventing further infection.

Laboratory tests have shown that just 5–10 minutes of chewing significantly reduces transmissible virus levels in saliva.


🦠 Why This Matters

This gum is not a cure, but a game-changing tool for prevention — especially in high-risk settings such as:

  • Dental clinics
  • Hospitals
  • Intimate partner situations
  • Populations vulnerable to herpes outbreaks or blood-borne infections

🛡️ Potential Public Health Benefits

  • May reduce oral-to-oral or oral-to-genital transmission of HSV
  • Offers a new layer of protection for immunocompromised individuals
  • Could aid in slowing the spread of viral infections during epidemic or pandemic outbreaks

Researchers emphasize that this gum could complement vaccines and antiviral drugs, not replace them.


📅 What’s Next?

The product is currently undergoing clinical trials in the U.S. and Europe. If successful, it could hit the market as early as late 2025, pending FDA and EU regulatory approval.


Final Thoughts

A simple piece of gum could soon become a powerful line of defense in the global fight against viral diseases. With the potential to reduce transmission rates and offer daily protection, this antiviral chewing gum marks an exciting advancement in the world of preventive medicine.


By ✍️ Yorlinda Ramìrez - MicuPost Team

Sources: